The efficacy of intravitreal piperacillin/tazobactam in rabbits with experimental Staphylococcus epidermidis endophthalmitis: A comparison with vancomycin

Ophthalmic Research

Volumn 37, Issue 3, 2005, Pages 168-174

  Özkiriş, Abdullah ^a,b   Evereklioglu, Cem ^a   Eşel, Duygu ^a   Akgün, Hülya ^a   Erkiliç, Kuddusi ^a  

^a ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^b Yildirim Beyazit Mah Mustafa Simsek   (Turkey)

Author keywords

Experimental S. epidermidis endophthalmitis; Intravitreal piperacillin tazobactam; Intravitreal vancomycin

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM; SODIUM CHLORIDE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EXAMINATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ENDOPHTHALMITIS; EYE; FEMALE; HISTOPATHOLOGY; INOCULATION; MALE; MICROBIOLOGICAL EXAMINATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM; STAPHYLOCOCCUS EPIDERMIDIS; STATISTICAL SIGNIFICANCE; VITREOUS BODY;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; INJECTIONS; MALE; PENICILLANIC ACID; PIPERACILLIN; RABBITS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; VANCOMYCIN; VITREOUS BODY;

EID: 22544462230     PISSN: 00303747     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086074     Document Type: Article

References (32)

1. Benz MS, Scott IU, Flynn HW Jr, Unonius N, Miller D: Endophthalmitis isolates and antibiotic sensitivities: A 6-year review of culture-proven cases. Am J Ophthalmol 2004;137:38-42.
2. Endophthalmitis Vitrectomy Study Group: Results of the endophthalmitis vitrectomy study. Arch Ophthalmol 1995;113:1479-1496.
3. O'Day DM, Jones DB, Patrinely J, Elliott JH: Staphylococcus epidermidis endophthalmitis: Visual outcome following noninvasive therapy. Ophthalmology 1982;89:354-360.
4. Alfaro DV, Runyan T, Kirkman E, Tran VT, Liggett PE: Intravenous cefazolin in penetrating eye injuries: Treatment of experimental posttraumatic endophthalmitis. Retina 1993;13:331-334.
5. Smith MA, Sorenson JA, D'Aversa G, Mandelbaum S, Udell I, Harrison W: Treatment of experimental methicillin-resistant Staphyhcoccus epidermidis endophthalmitis with intravitreal vancomycin and intravitreal dexamethasone. J Infect Dis 1997;175:462-466.
6. Karakucuk S, Mirza E, Sumerkan B, Okten T: Intravitreal trovafloxacin against experimental Staphylococcus epidermidis endophthalmitis. Ophthalmic Res 2000;32:126-131.
7. Sanders WE, Sanders CC: Piperacillin/tazobactam: A critical review of the evolving clinical literature. Clin Infect Dis 1996;22:107-123.
8. Okereke C, Dudley MN: Beta-lactam/beta-lactamase inhibitor combinations: Pharmacodynamic considerations and possible role in the management of bacterial infections in the neutropenic host. J Antimicrob Chemother 1998;41:43-49.
9. Bryson HM, Brogden RN: Piperacillin/tazobactam: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-535.
10. Acar JF, Goldstein FW, Kitzis MD: Susceptibility survey of piperacillin alone and in the presence of tazobactam. J Antimicrob Chemother 1993;31:23-28.
11. Platsouka E, Zissis NP, Portolos J, Paniara O: Bacterial susceptibilities to piperacillin/tazobactam in a tertiary care hospital: 5-year review. J Chemother 2003;15:27-30.
12. Ozkiris A, Evereklioglu C, Kontaş O, Oner A, Erkilic K: Determination of non-toxic concentrations of piperacillin/tazobactam for intravitreal application: An electroretinographic, histopathologic and morphometric analysis. Ophthalmic Res 2004;36:139-144.
13. Hindler J: Antimicrobial susceptibility testing; in Isenberg HD (ed): Essential Procedures for Clinical Microbiology. Washington, American Society for Microbiology, 1998, pp 205-215.
14. Evereklioglu C, Ozkiris A, Alasehirli B, Sari I, Guldur E, Cengiz B, Kontas O: Effect of gestational nicotine treatment on newborn rat retina: A histopathological and morphometric analysis. Ophthalmic Physiol Opt 2003;23:527-533.
15. Evereklioglu C, Sari I, Alasehirli B, Guldur E, Cengiz B, Balat O, Bagci C: High dose of maternal caffeine administered to pregnant rats causes histopathological changes in the cornea of newborn pups. Med Sci Monitor 2003;9:168-173.
16. Ryan EH, Mizener JB: Tissue plasminogen activator and Staphylococcus epidermidis endophthalmitis. Arch Ophthalmol 1993;111:1117-1122.
17. Goudron P, Jones DL, Dalton HP, Archer GL: Evaluation of laboratory tests for detection of methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. J Clin Microbiol 1986;24:764-769.
18. Meredith TA, Trabelsi A, Miller MJ, Aguilar E, Wilson LA: Spontaneous sterilization in experimental Staphylococcus epidermidis endophthalmitis. Invest Ophthalmol Vis Sci 1990;31:181-186.
19. Speaker MG, Milch FA, Shah MK, Eisner W, Kreiswirth BN: Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology 1991;98:639-649.
20. Mandelbaum S, Forster RK: Exogenous endophtkalmitis; in Pepose JS, Holland GN, Wilhelmus KR (eds): Ocular Infection and Immunity. St Louis, Mosby, 1995, pp 1298-1317.
21. Aaberg TM, Flynn HW, Schiffman J, Newton J: Nosocomial acute-onset postoperative endophthalmitis survey: A 10-year review of incidence and outcomes. Ophthalmology 1998;105:1004-1010.
22. Endophthalmitis Vitrectomy Study Group: Microbiologic factors and visual outcome in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol 1996;122:830-846.
23. Pleyer U, Mondino BJ, Adamu SA, Pitchekian-Halabi H, Engstrom RE, Glasgow BJ: Immune response to Staphylococcus epidermidis-induced endophthalmitis in a rabbit model. Invest Ophthalmol Vis Sci 1992;33:2650-2663.
24. Ormerod LD, Ho DD, Becker LE, Cruise RJ, Grohar HI, Paton BG, Frederick AR Jr, Topping TM, Weiter JJ, Buzney SM: Endophthalmitis caused by the coagulase-negative staphylococci: Disease spectrum and outcome. Ophthalmology 1993;100:715-723.
25. Quie PG, Belani KK: Coagulase-negative staphylococcal adherence and persistence. J Infect Dis 1987;156:543-547.
26. Schmidt H, Schloricke E, Fislage R, Schulze HA, Guthoff R: Effect of surface modifications of intraocular lenses on the adherence of Staphylococcus epidermidis. Zentralbl Bakteriol 1998;287:135-145.
27. Hassan IJ: Endophthalmitis: Problems, progress and prospects. J Antimicrob Chemother 1994;33:383-386.
28. Perry CM, Markham A: Piperacillin/tazobactam: An updated review of its use in the treatment of bacterial infections. Drugs 1999;57:805-843.
29. Ambrose PG, Bhavnani SM, Jones RN: Pharmacokinetics-pharmacodynamics of cefepime and piperacillin- tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases: Report from the ARREST Program. Antimicrob Agents Chemother 2003;47:1643-1646.
30. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, Maravi-Poma E, Torres-Marti A, Nava J, Martinez-Pellus A, Palomar M, Barcenilla F: Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: A prospective randomized multicenter trial. Intensive Care Med 2001;27:493-502.
31. Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP: Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 2002;48:59-63.
32. Tallis E, Rudensky B, Attias D, Raveh D, Schlesinger Y, Yinnon AM: In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus. Diagn Microbiol Infect Dis 1999;35:121-126.